Thor Halfdanarson: Observation of small pancreatic NETs is becoming a standard
Thor Halfdanarson, Hematologist and oncologist at Mayo Clinic, shared on X a recent paper by Susumu Hijioka et al. titled “Factors Affecting Nonfunctioning Small Pancreatic Neuroendocrine Neoplasms and Proposed New Treatment Strategies” published in Science Direct.
Authors: Susumu Hijioka, Daiki Yamashige, Minoru Esaki, Goro Honda, Ryota Higuchi, Toshihiko Masui, Yasuhiro Shimizu, Masayuki Ohtsuka, Yusuke Kumamoto et al.
“Observation of small (≤2cm) pancreatic NETs is widely accepted and becoming a standard. Maybe it is a little more nuanced… Should we take into account tumor grade as well as stage re-resection? Small G2 pNETs are more likely than G1 to be N+ (15% vs. 3%).
I meant to say size and not stage above but I guess you know what I meant to say…
Stefano Partelli, I suspect you will have more data coming from the ASPEN study regarding but as I recall, <10% of patients there had documented G2 primary NETs”
Source: Thor Halfdanarson/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023